Value of serum procalcitonin levels in the differential diagnosis of pneumonia and pulmonary embolism Source: Annual Congress 2011 - Assessment of severity and predictors of outcomes in community-acquired pneumonia Year: 2011
Serum procalcitonin concentrations in children with pulmonary tuberculosis, tuberculous infection and lober pneumonia Source: Eur Respir J 2003; 22: Suppl. 45, 176s Year: 2003
Serum IFN-γ and TNF-α levels in pulmonary tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 456s Year: 2005
Usefulness of C-reactive protein and procalcitonin levels in pulmonary tuberculosis Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014
Comparison of serum CA-125 levels in pulmonary tuberculosis, pleural tuberculosis and treated active pulmonary tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 453s Year: 2005
The diagnostic value of serum procalcitonin in differential diagnosis of pulmonary embolism and pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 462s Year: 2007
Evaluation of sICAM-1 as a serum marker for follow-up of pulmonary tuberculosis therapy Source: Eur Respir J 2005; 26: Suppl. 49, 454s Year: 2005
High serum procalcitonin and C-reactive protein levels can exclude tuberculosis in community-acquired pneumonia patients with atypical presentation Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010
High serum CA-125 level in active pulmonary tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 415s Year: 2005
The relation of serum interleukin-6 and C-reactive protein to clinical parameters in pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 35s Year: 2004
Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia Source: Eur Respir J 2005; 25: 688-692 Year: 2005
Serum Procalcitonin for diagnosing and monitoring response in pleural infection Source: International Congress 2019 – Pleural infection and complicated pneumonia Year: 2019
Utility of procalcitonin, neopterin, C-reactive protein and MR-proANP measurement in the management of exacerbations in chronic obstructive pulmonary disease Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008
C-reactive protein in pulmonary TB Source: Annual Congress 2009 - Diagnostic advances in tuberculosis Year: 2009
Evaluation of D-dimer levels in patients with active pulmonary tuberculosis and latent tuberculosis infection Source: Eur Respir J 2006; 28: Suppl. 50, 164s Year: 2006
Usefulness of inflammatory markers: procalcitonin, neopterin, C-reactive protein and MR-proANP in the follow-up of patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008
The significance of serum CA-125 and various tumour markers in pulmonary and pleural tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 156s Year: 2003
Elevated serum adiponectin level in patients with mycobacterium avium-intracellulare complex pulmonary disease Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis Year: 2008
The relationship between level of C-reactive protein in blood serum and clinical manifestations of the disease in patients with pulmonary tuberculosis Source: Annual Congress 2010 - Tuberculosis: metabolic insights Year: 2010
High serum periostin levels and the association with pulmonary tuberculosis Source: International Congress 2018 – Diagnosis of tuberculosis Year: 2018